Dr. Anthony A Somogyi, General Practice Medicare: Medicare Enrolled Practice Location: 4401 Francis Lewis Blvd Ste L3b, Bayside, NY 11361 Phone: 718-224-5687 Fax: 718-224-5746 |
Dr. Eric Pinto, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 20215 56th Ave, Bayside, NY 11364 Phone: 718-767-3411 |
Ms. Felicitas Soriano Lu, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 209 - 33 26 Ave., 3-d, Bayside, NY 11360 Phone: 718-631-7156 Fax: 718-631-7156 |
News Archive
New research into the fight against Dengue, an insect-borne tropical disease that infects up to 390 million people worldwide annually, may influence the development of anti-viral therapies that are effective against all four types of the virus.
At the 46th Annual Meeting of the Society for Neuroscience, Bruker today announced the release of the Ultima NeuraLight 3D simultaneous, all-optical stimulation and imaging platform for neuroscience applications.
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.
A physician-researcher from The Children's Hospital of Philadelphia will lead the first-ever pediatric "Dream Team" solely focused on creating new treatments for the most challenging childhood cancers.
The test uses a chemical called florbetapir, known by the brand name Amyvid, which is a radioactive agent that tags clumps of a sticky substance called an amyloid. Amyloid proteins are hallmarks of Alzheimer's disease. The chemical, which costs $1,600 per dose, then is detected using a brain imaging technique called positron emission tomography, known as PET scans. For patients who already have some symptoms of cognitive decline, a positive scan suggests that moderate to frequent amyloid plaques are present in the brain, which is consistent with Alzheimer's disease.
› Verified 6 days ago